Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
X-Linked Combined Immunodeficiency Diseases
0.040 Biomarker group BEFREE While currently available preclinical safety models have been used for evaluating vector safety, none have predicted or reproduced the recurrent LMO2 integrations seen in previous X-linked severe combined immunodeficiency (X-SCID) and Wiskott-Aldrich clinical gene therapy trials. 26957223 2016
X-Linked Combined Immunodeficiency Diseases
0.040 AlteredExpression group BEFREE Here, we show that the genes and signaling pathways deregulated in murine leukemias with retroviral insertions at Lmo2 are similar to those deregulated in human leukemias with high LMO2 expression and are highly predictive of the leukemias induced in SCID-X1 patients. 19461887 2009
X-Linked Combined Immunodeficiency Diseases
0.040 AlteredExpression group BEFREE Pathogenic activation of the LMO2 proto-oncogene by an oncoretroviral vector insertion in a clinical trial for X-linked severe combined immunodeficiency (X-SCID) has prompted safety concerns. 17991809 2008
X-Linked Combined Immunodeficiency Diseases
0.040 AlteredExpression group BEFREE Recent reports linking insertional activation of LMO2 following gene therapy for X-linked severe combined immunodeficiency (X-SCID) have led to a re-evaluation of risks following gene therapy with retroviral vectors. 15933056 2005